Methods Table 3. Commonly Used Abbreviations and Their Expansions

[ Print version ][ PDF version ]
Abbreviation Expansion or Notes
These terms are not expanded in text
HCV hepatitis C virus. In this Guidance "hepatitis C virus" and HCV refer to the virus. Hepatitis C and HCV infection or HCV disease refer to the resulting disease.
IFN interferon alfa
PEG peginterferon alfa
These terms are expanded at first mention in text
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the curve
BOC boceprevir
CBC complete blood cell (eg, complete blood cell count)
CrCl creatinine clearance
CTP Child Turcotte Pugh (see below)
DAA direct-acting antiviral
ESRD end-stage renal disease
FDA Food and Drug Administration
GFR glomerular filtration rate
HBsAg hepatitis B virus surface antigen
HBV hepatitis B virus
HCC hepatocellular carcinoma
IDU injection drug use or user
INR international normalized ratio
MELD model for end-stage liver disease
MSM men who have sex with men
NAT nucleic acid testing
NIH National Institutes of Health
OATP organic anion-transporting polypeptide
P-gp p-glycoprotein
PrOD paritaprevir/ritonavir/ombitasvir plus dasabuvir
RAV resistance-associated variant
RBC red blood cell (eg, red blood cell count)
RBV ribavirin
RGT response-guided therapy
RVR rapid virologic response
sAg surface antigen
SMV simeprevir; used for the treatment of those with genotype 1 of hepatitis C virus (HCV) who have compensated liver disease, including cirrhosis
SOF sofosbuvir; a nucleoside analogue used in combination with other drugs for the treatment of HCV infection
SVR12 (or 24 or 48, etc) sustained virologic response at 12 weeks (or at 24 weeks, or at 48 weeks, etc)
TSH thyroid-stimulating hormone
TVR telaprevir; an antiviral agent to treat hepatitis C
Definition of Terms
Child Turcotte Pugh (CTP) classification of the severity of cirrhosis
  Class A Class B Class C
Total points 5–6 7–9 10–15
Factor 1 Point 2 Points 3 Points
Total bilirubin (µmol/L) <34 34–50 >50
Serum albumin (g/L) >35 28–35 <28
Prothrombin time/international normalized ratio <1.7 1.71–2.30 >2.30
Ascites None Mild Moderate to Severe
Hepatic encephalopathy None Grade I–II (or suppressed with medication) Grade III–IV (or refractory)
IFN ineligible IFN ineligible is defined as one or more of the below:
  • Intolerance to IFN
  • Autoimmune hepatitis and other autoimmune disorders
  • Hypersensitivity to PEG or any of its components
  • Decompensated hepatic disease
  • Major uncontrolled depressive illness
  • A baseline neutrophil count below 1500/µL, a baseline platelet count below 90,000/µL or baseline hemoglobin below 10 g/dL
  • A history of preexisting cardiac disease
Relapser a person who has achieved an undetectable level of virus during a prior treatment course of PEG/RBV and relapsed after treatment was stopped


Changes made September 16, 2016.